10 records totalling $4,621,227.00 CAD, from official Government of Canada open data.
| National Research Council Canada | $4,621,227 | 10 records |
This project builds on the success of the work done over the last two years in establishing clinical grade manufacturing for both lentivirus and cell products, and in executing the first clinical tria...
This project builds on the success of the work done over the last two years in establishing clinical grade manufacturing for both lentivirus and cell products, and in executing the first clinical tria...
This project build on the success of the work done over the last two years in establishing clinical grade manufacturing for both lentivirus and cell products, and in executing the first clinical trial...
Immunotherapy has yielded disappointing results against ovarian cancer, prompting the need for bold new approaches. Chimeric Antigen Receptor (CAR) T cells have proven phenomenally successful against...
Designing a drug for a specific disease type is highly challenging due to tremendous molecular search space and limited understanding about the disease of interest. Successful discovery of a medicine...
Designing a drug for a specific disease type is highly challenging due to tremendous molecular search space and limited understanding about the disease of interest. Successful discovery of a medicine...
The main goal of this work is to create a made-in-Canada clinical ready approach for genome editing of CAR-T for cancer immunotherapy. The project aims to enhance the potency of single-domain antibody...
The main goal of this work is to create a made-in-Canada clinical ready approach for genome editing of CAR-T for cancer immunotherapy. The project aims to enhance the potency of single-domain antibody...
This project will develop a lead candidate anti-CD22 CAR (Chimeric Antigen Receptor) comprising a camelid antibody derived anti-CD22 binding domain (developed by NRC) in the context of a CAR backbone...
Advances exploratory research under the New Beginnings Initiative